| Year |
Citation |
Score |
| 2024 |
Aldous SG, Smith EJ, Landles C, Osborne GF, Cañibano-Pico M, Nita IM, Phillips J, Zhang Y, Jin B, Hirst MB, Benn CL, Bond BC, Edelmann W, Greene JR, Bates GP. A CAG repeat threshold for therapeutics targeting somatic instability in Huntington's disease. Brain : a Journal of Neurology. PMID 38387080 DOI: 10.1093/brain/awae063 |
0.762 |
|
| 2024 |
Bondulich MK, Phillips J, Cañibano-Pico M, Nita IM, Byrne LM, Wild EJ, Bates GP. Translatable plasma and CSF biomarkers for use in mouse models of Huntington's disease. Brain Communications. 6: fcae030. PMID 38370446 DOI: 10.1093/braincomms/fcae030 |
0.328 |
|
| 2023 |
Smith EJ, Sathasivam K, Landles C, Osborne GF, Mason MA, Gomez-Paredes C, Taxy BA, Milton RE, Ast A, Schindler F, Zhang C, Duan W, Wanker EE, Bates GP. Early detection of exon 1 huntingtin aggregation in zQ175 brains by molecular and histological approaches. Brain Communications. 5: fcad010. PMID 36756307 DOI: 10.1093/braincomms/fcad010 |
0.329 |
|
| 2022 |
Geijtenbeek KW, Janzen J, Bury AE, Sanz-Sanz A, Hoebe RA, Bondulich MK, Bates GP, Reits EAJ, Schipper-Krom S. Reduction in PA28αβ activation in HD mouse brain correlates to increased mHTT aggregation in cell models. Plos One. 17: e0278130. PMID 36574405 DOI: 10.1371/journal.pone.0278130 |
0.436 |
|
| 2022 |
Fienko S, Landles C, Sathasivam K, McAteer SJ, Milton RE, Osborne GF, Smith EJ, Jones ST, Bondulich MK, Danby ECE, Phillips J, Taxy BA, Kordasiewicz HB, Bates GP. Alternative processing of human HTT mRNA with implications for Huntington's disease therapeutics. Brain : a Journal of Neurology. PMID 35793238 DOI: 10.1093/brain/awac241 |
0.393 |
|
| 2022 |
Gu X, Richman J, Langfelder P, Wang N, Zhang S, Bañez-Coronel M, Wang HB, Yang L, Ramanathan L, Deng L, Park CS, Choi CR, Cantle JP, Gao F, Gray M, ... ... Bates GP, et al. Uninterrupted CAG repeat drives striatum-selective transcriptionopathy and nuclear pathogenesis in human Huntingtin BAC mice. Neuron. PMID 35114102 DOI: 10.1016/j.neuron.2022.01.006 |
0.39 |
|
| 2021 |
Schulze-Krebs A, Canneva F, Stemick J, Plank AC, Harrer J, Bates GP, Aeschlimann D, Steffan JS, von Hörsten S. Transglutaminase 6 Is Colocalized and Interacts with Mutant Huntingtin in Huntington Disease Rodent Animal Models. International Journal of Molecular Sciences. 22. PMID 34445621 DOI: 10.3390/ijms22168914 |
0.393 |
|
| 2021 |
Schindler F, Praedel N, Neuendorf N, Kunz S, Schnoegl S, Mason MA, Taxy BA, Bates GP, Khoshnan A, Priller J, Grimm J, Maier M, Boeddrich A, Wanker EE. Small, Seeding-Competent Huntingtin Fibrils Are Prominent Aggregate Species in Brains of zQ175 Huntington's Disease Knock-in Mice. Frontiers in Neuroscience. 15: 682172. PMID 34239412 DOI: 10.3389/fnins.2021.682172 |
0.35 |
|
| 2021 |
Gomez-Paredes C, Mason MA, Taxy BA, Papadopoulou AS, Paganetti P, Bates GP. The heat shock response, determined by QuantiGene multiplex, is impaired in HD mouse models and not caused by HSF1 reduction. Scientific Reports. 11: 9117. PMID 33907289 DOI: 10.1038/s41598-021-88715-5 |
0.323 |
|
| 2021 |
Zhou Y, Peskett TR, Landles C, Warner JB, Sathasivam K, Smith EJ, Chen S, Wetzel R, Lashuel HA, Bates GP, Saibil HR. Correlative light and electron microscopy suggests that mutant huntingtin dysregulates the endolysosomal pathway in presymptomatic Huntington's disease. Acta Neuropathologica Communications. 9: 70. PMID 33853668 DOI: 10.1186/s40478-021-01172-z |
0.315 |
|
| 2021 |
Bondulich MK, Fan Y, Song Y, Giorgini F, Bates GP. Ablation of kynurenine 3-monooxygenase rescues plasma inflammatory cytokine levels in the R6/2 mouse model of Huntington's disease. Scientific Reports. 11: 5484. PMID 33750843 DOI: 10.1038/s41598-021-84858-7 |
0.355 |
|
| 2021 |
Landles C, Milton RE, Jean A, McLarnon S, McAteer SJ, Taxy BA, Osborne GF, Zhang C, Duan W, Howland D, Bates GP. Development of novel bioassays to detect soluble and aggregated Huntingtin proteins on three technology platforms. Brain Communications. 3: fcaa231. PMID 33604571 DOI: 10.1093/braincomms/fcaa231 |
0.322 |
|
| 2020 |
Landles C, Milton RE, Ali N, Flomen R, Flower M, Schindler F, Gomez-Paredes C, Bondulich MK, Osborne GF, Goodwin D, Salsbury G, Benn CL, Sathasivam K, Smith EJ, Tabrizi SJ, ... ... Bates GP, et al. Subcellular Localization And Formation Of Huntingtin Aggregates Correlates With Symptom Onset And Progression In A Huntington'S Disease Model. Brain Communications. 2: fcaa066. PMID 32954323 DOI: 10.1093/braincomms/fcaa066 |
0.78 |
|
| 2020 |
Mason MA, Gomez-Paredes C, Sathasivam K, Neueder A, Papadopoulou AS, Bates GP. Silencing Srsf6 does not modulate incomplete splicing of the huntingtin gene in Huntington's disease models. Scientific Reports. 10: 14057. PMID 32820193 DOI: 10.1038/s41598-020-71111-w |
0.494 |
|
| 2020 |
Hegde RN, Chiki A, Petricca L, Martufi P, Arbez N, Mouchiroud L, Auwerx J, Landles C, Bates GP, Singh-Bains MK, Dragunow M, Curtis MA, Faull RL, Ross CA, Caricasole A, et al. TBK1 phosphorylates mutant Huntingtin and suppresses its aggregation and toxicity in Huntington's disease models. The Embo Journal. e104671. PMID 32757223 DOI: 10.15252/Embj.2020104671 |
0.407 |
|
| 2020 |
Ghosh R, Wood-Kaczmar A, Dobson L, Smith EJ, Sirinathsinghji EC, Kriston-Vizi J, Hargreaves IP, Heaton R, Herrmann F, Abramov AY, Lam AJ, Heales SJ, Ketteler R, Bates GP, Andre R, et al. Expression of mutant exon 1 huntingtin fragments in human neural stem cells and neurons causes inclusion formation and mitochondrial dysfunction. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. PMID 32329133 DOI: 10.1096/fj.201902277RR |
0.39 |
|
| 2020 |
Nath SR, Lieberman ML, Yu Z, Marchioretti C, Jones ST, Danby ECE, Van Pelt KM, Sorarù G, Robins DM, Bates GP, Pennuto M, Lieberman AP. MEF2 impairment underlies skeletal muscle atrophy in polyglutamine disease. Acta Neuropathologica. PMID 32306066 DOI: 10.1007/s00401-020-02156-4 |
0.33 |
|
| 2019 |
Papadopoulou AS, Gomez-Paredes C, Mason MA, Taxy BA, Howland D, Bates GP. Extensive Expression Analysis of Htt Transcripts in Brain Regions from the zQ175 HD Mouse Model Using a QuantiGene Multiplex Assay. Scientific Reports. 9: 16137. PMID 31695145 DOI: 10.1038/s41598-019-52411-2 |
0.465 |
|
| 2019 |
Irvine EE, Katsouri L, Plattner F, Al-Qassab H, Al-Nackkash R, Bates GP, Withers DJ. Genetic deletion of S6k1 does not rescue the phenotypic deficits observed in the R6/2 mouse model of Huntington's disease. Scientific Reports. 9: 16133. PMID 31695068 DOI: 10.1038/s41598-019-52391-3 |
0.533 |
|
| 2019 |
Franich NR, Hickey MA, Zhu C, Osborne GF, Ali N, Chu T, Bove NH, Lemesre V, Lerner RP, Zeitlin SO, Howland D, Neueder A, Landles C, Bates GP, Chesselet MF. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene. Journal of Neuroscience Research. PMID 31282030 DOI: 10.1002/Jnr.24493 |
0.493 |
|
| 2019 |
Pido-Lopez J, Tanudjojo B, Farag S, Bondulich MK, Andre R, Tabrizi SJ, Bates GP. Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington's disease by etanercept treatment. Scientific Reports. 9: 7202. PMID 31076648 DOI: 10.1038/s41598-019-43627-3 |
0.484 |
|
| 2019 |
Reindl W, Baldo B, Schulz J, Janack I, Lindner I, Kleinschmidt M, Sedaghat Y, Thiede C, Tillack K, Schmidt C, Cardaun I, Schwagarus T, Herrmann F, Hotze M, Osborne GF, ... ... Bates GP, et al. Meso scale discovery-based assays for the detection of aggregated huntingtin. Plos One. 14: e0213521. PMID 30913220 DOI: 10.1371/journal.pone.0213521 |
0.439 |
|
| 2018 |
Neueder A, Dumas AA, Benjamin AC, Bates GP. Regulatory mechanisms of incomplete huntingtin mRNA splicing. Nature Communications. 9: 3955. PMID 30262848 DOI: 10.1038/s41467-018-06281-3 |
0.382 |
|
| 2018 |
Ast A, Buntru A, Schindler F, Hasenkopf R, Schulz A, Brusendorf L, Klockmeier K, Grelle G, McMahon B, Niederlechner H, Jansen I, Diez L, Edel J, Boeddrich A, Franklin SA, ... ... Bates GP, et al. mHTT Seeding Activity: A Marker of Disease Progression and Neurotoxicity in Models of Huntington's Disease. Molecular Cell. 71: 675-688.e6. PMID 30193095 DOI: 10.1016/J.Molcel.2018.07.032 |
0.511 |
|
| 2018 |
Pido-Lopez J, Andre R, Benjamin AC, Ali N, Farag S, Tabrizi SJ, Bates GP. In vivo neutralization of the protagonist role of macrophages during the chronic inflammatory stage of Huntington's disease. Scientific Reports. 8: 11447. PMID 30061661 DOI: 10.1038/s41598-018-29792-x |
0.386 |
|
| 2018 |
Farshim PP, Bates GP. Mouse Models of Huntington's Disease. Methods in Molecular Biology (Clifton, N.J.). 1780: 97-120. PMID 29856016 DOI: 10.1007/978-1-4939-7825-0_6 |
0.485 |
|
| 2018 |
Neueder A, Bates GP. RNA Related Pathology in Huntington's Disease. Advances in Experimental Medicine and Biology. 1049: 85-101. PMID 29427099 DOI: 10.1007/978-3-319-71779-1_4 |
0.404 |
|
| 2018 |
Smith E, Sathasivam K, Bates G. B17 Establishing a neural progenitor cell model of huntington’s disease Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.69 |
0.393 |
|
| 2018 |
Mason MA, Paredes CG, Papadopoulou AS, Bates GP. A04 The role of splicing factor SRSF6 in incomplete splicing of the HTT transcript Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.4 |
0.423 |
|
| 2018 |
Neueder A, Dumas AA, Benjamin AC, Bates GP. A03 Regulatory mechanisms of incomplete HTT MRNA splicing in huntington’s disease Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.3 |
0.391 |
|
| 2018 |
Riggall L, Siow B, Golay X, Bates G. A31 The development of translational biomarkers of neuroinflammation in a mouse model of huntington’s disease Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.29 |
0.489 |
|
| 2018 |
Schulze-Krebs A, Canneva F, Schnepf R, Gloßner L, Plank A, Dobner J, Bates GP, Aeschlimann D, Steffan JS, Hörsten Sv. A20 A role for transglutaminase 6 in hd pathology Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.19 |
0.467 |
|
| 2018 |
Paredes CG, Mason MA, McAteer S, Papadopoulou AS, Bates GP. A18 Investigating the mechanisms of the heat shock response impairment in huntington’s disease Journal of Neurology, Neurosurgery, and Psychiatry. 89. DOI: 10.1136/Jnnp-2018-Ehdn.17 |
0.402 |
|
| 2017 |
Baron O, Boudi A, Dias C, Schilling M, Nölle A, Vizcay-Barrena G, Rattray I, Jungbluth H, Scheper W, Fleck RA, Bates GP, Fanto M. Stall in Canonical Autophagy-Lysosome Pathways Prompts Nucleophagy-Based Nuclear Breakdown in Neurodegeneration. Current Biology : Cb. 27: 3626-3642.e6. PMID 29174892 DOI: 10.1016/j.cub.2017.10.054 |
0.423 |
|
| 2017 |
Bondulich MK, Jolinon N, Osborne GF, Smith EJ, Rattray I, Neueder A, Sathasivam K, Ahmed M, Ali N, Benjamin AC, Chang X, Dick JRT, Ellis M, Franklin SA, Goodwin D, ... ... Bates GP, et al. Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington's disease mice. Scientific Reports. 7: 14275. PMID 29079832 DOI: 10.1038/S41598-017-14290-3 |
0.385 |
|
| 2017 |
Neueder A, Gipson TA, Batterton S, Lazell HJ, Farshim PP, Paganetti P, Housman DE, Bates GP. HSF1-dependent and -independent regulation of the mammalian in vivo heat shock response and its impairment in Huntington's disease mouse models. Scientific Reports. 7: 12556. PMID 28970536 DOI: 10.1038/s41598-017-12897-0 |
0.348 |
|
| 2017 |
Bryant DT, Landles C, Papadopoulou AS, Benjamin AC, Duckworth JK, Rosahl T, Benn CL, Bates GP. Disruption to schizophrenia-associated gene Fez1 in the hippocampus of HDAC11 knockout mice. Scientific Reports. 7: 11900. PMID 28928414 DOI: 10.1038/s41598-017-11630-1 |
0.722 |
|
| 2017 |
Neueder A, Landles C, Ghosh R, Howland D, Myers RH, Faull RLM, Tabrizi SJ, Bates GP. The pathogenic exon 1 HTT protein is produced by incomplete splicing in Huntington's disease patients. Scientific Reports. 7: 1307. PMID 28465506 DOI: 10.1038/S41598-017-01510-Z |
0.494 |
|
| 2017 |
Rattray I, Smith EJ, Crum WR, Walker TA, Gale R, Bates GP, Modo M. Correlations of Behavioral Deficits with Brain Pathology Assessed through Longitudinal MRI and Histopathology in the HdhQ150/Q150 Mouse Model of Huntington's Disease. Plos One. 12: e0168556. PMID 28099507 DOI: 10.1371/journal.pone.0168556 |
0.312 |
|
| 2016 |
Osmand AP, Bichell TJ, Bowman AB, Bates GP. Embryonic Mutant Huntingtin Aggregate Formation in Mouse Models of Huntington's Disease. Journal of Huntington's Disease. PMID 27886014 DOI: 10.3233/JHD-160217 |
0.448 |
|
| 2016 |
Jansen AH, van Hal M, Op den Kelder IC, Meier RT, de Ruiter AA, Schut MH, Smith DL, Grit C, Brouwer N, Kamphuis W, Boddeke HW, den Dunnen WF, van Roon WM, Bates GP, Hol EM, et al. Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell-type-specific. Glia. PMID 27615381 DOI: 10.1002/glia.23050 |
0.439 |
|
| 2016 |
Hjerpe R, Bett JS, Keuss MJ, Solovyova A, McWilliams TG, Johnson C, Sahu I, Varghese J, Wood N, Wightman M, Osborne G, Bates GP, Glickman MH, Trost M, Knebel A, et al. UBQLN2 Mediates Autophagy-Independent Protein Aggregate Clearance by the Proteasome. Cell. PMID 27477512 DOI: 10.1016/j.cell.2016.07.001 |
0.354 |
|
| 2016 |
Kakkar V, Månsson C, de Mattos EP, Bergink S, van der Zwaag M, van Waarde MA, Kloosterhuis NJ, Melki R, van Cruchten RT, Al-Karadaghi S, Arosio P, Dobson CM, Knowles TP, Bates GP, van Deursen JM, et al. The S/T-Rich Motif in the DNAJB6 Chaperone Delays Polyglutamine Aggregation and the Onset of Disease in a Mouse Model. Molecular Cell. PMID 27151442 DOI: 10.1016/J.Molcel.2016.03.017 |
0.404 |
|
| 2016 |
Tulino R, Benjamin AC, Jolinon N, Smith DL, Chini EN, Carnemolla A, Bates GP. Correction: SIRT1 Activity Is Linked to Its Brain Region-Specific Phosphorylation and Is Impaired in Huntington's Disease Mice. Plos One. 11: e0150682. PMID 26919088 DOI: 10.1371/journal.pone.0150682 |
0.393 |
|
| 2016 |
Tulino R, Benjamin AC, Jolinon N, Smith DL, Chini EN, Carnemolla A, Bates GP. SIRT1 Activity Is Linked to Its Brain Region-Specific Phosphorylation and Is Impaired in Huntington's Disease Mice. Plos One. 11: e0145425. PMID 26815359 DOI: 10.1371/journal.pone.0145425 |
0.474 |
|
| 2016 |
Mason M, Flomen R, Bates GP. B38 The effect of Hdac4 reduction post-weaning on hd-related phenotypes in R6/2 mice Journal of Neurology, Neurosurgery & Psychiatry. 87: A22.2-A22. DOI: 10.1136/jnnp-2016-314597.69 |
0.431 |
|
| 2016 |
Wood-Kaczmar A, Ghosh R, Kriston-Vizi J, Smith EJ, Chadwick W, Hargreaves IP, Heales SJ, Abramov AY, Cole SL, Ketteler R, Bates GP, Andre R, Tabrizi SJ. B27 Abnormal bioenergetics in inclusion-containing mutant HTT exon 1 primary human neurons Journal of Neurology, Neurosurgery & Psychiatry. 87: A18.2-A19. DOI: 10.1136/jnnp-2016-314597.58 |
0.376 |
|
| 2016 |
Pido-Lopez J, Andre R, Benjamin A, Franklin SA, Tabrizi SJ, Bates GP. B24 Assessment of immune system activation status during the course of disease in huntington’s disease mouse model Journal of Neurology, Neurosurgery & Psychiatry. 87: A17.2-A17. DOI: 10.1136/jnnp-2016-314597.55 |
0.386 |
|
| 2016 |
Ghosh R, Wood-Kaczmar A, Andre R, Kriston-Vizi J, Ketteler R, Cole S, Smith EJ, Bates GP, Tabrizi SJ. B10 Inclusion formation in mutant HTT exon 1 expressing human neuronal cells Journal of Neurology, Neurosurgery & Psychiatry. 87: A12.2-A12. DOI: 10.1136/jnnp-2016-314597.41 |
0.322 |
|
| 2016 |
Sathasivam K, Paredes CG, Kuhlbrodt K, Thiede C, Reindl W, Smith EJ, Benjamin AC, Franklin SA, Whitehouse CA, Herrmann F, Tillack K, Macdonald D, Marchionini D, Bates GP. B8 Ablation of p62 modulates levels of soluble and aggregated mutant huntingtin and delays end-stage disease in R6/2 mice Journal of Neurology, Neurosurgery & Psychiatry. 87: A11.3-A12. DOI: 10.1136/JNNP-2016-314597.39 |
0.455 |
|
| 2016 |
Bates GP, Osborne GF, Ali N, Benjamin AC, Papadopoulou AS, Howland D, Tabrizi SJ, Faull RL, Myers RH, Landles C, Neueder A. B4 Detection of the aberrantly spliced exon 1 – intron 1 htt mRNA in HD patient post mortem brain tissue and fibroblast lines Journal of Neurology, Neurosurgery & Psychiatry. 87: A10.2-A10. DOI: 10.1136/Jnnp-2016-314597.35 |
0.403 |
|
| 2016 |
Ali NS, Osborne GF, Benjamin AC, Sathasivam K, Neueder A, Howland D, Bates GP. B3 Comparison of the effect of a pure CAG repeat and mixed cagcaa repeat on the extent to which the htt gene is aberrantly spliced in knock-in mice Journal of Neurology, Neurosurgery & Psychiatry. 87: A10.1-A10. DOI: 10.1136/jnnp-2016-314597.34 |
0.366 |
|
| 2016 |
Farshim PP, Deverman BE, Bates GP. L3 Systemic administration of a novel AAV variant results in widespread and efficient gene transfer in R6/2 mice Journal of Neurology, Neurosurgery & Psychiatry. 87: A91.1-A91. DOI: 10.1136/Jnnp-2016-314597.258 |
0.433 |
|
| 2015 |
Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ, Tabrizi SJ. Huntington disease. Nature Reviews. Disease Primers. 1: 15005. PMID 27188817 DOI: 10.1038/nrdp.2015.5 |
0.343 |
|
| 2015 |
McCourt AC, O'Donovan KL, Ekblad E, Sand E, Craufurd D, Rosser A, Sanders D, Stoy N, Rickards H, Wierup N, Bates GP, Björkqvist M, Quarrell O. Characterization of Gastric Mucosa Biopsies Reveals Alterations in Huntington's Disease. Plos Currents. 7. PMID 26581667 DOI: 10.1371/Currents.Hd.858B4Cc7F235Df068387E9C20C436A79 |
0.366 |
|
| 2015 |
Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ. Treating the whole body in Huntington's disease. The Lancet. Neurology. 14: 1135-42. PMID 26466780 DOI: 10.1016/S1474-4422(15)00177-5 |
0.458 |
|
| 2015 |
Carnemolla A, Lazell H, Moussaoui S, Bates GP. In Vivo Profiling Reveals a Competent Heat Shock Response in Adult Neurons: Implications for Neurodegenerative Disorders. Plos One. 10: e0131985. PMID 26134141 DOI: 10.1371/journal.pone.0131985 |
0.348 |
|
| 2015 |
Stroedicke M, Bounab Y, Strempel N, Klockmeier K, Yigit S, Friedrich RP, Chaurasia G, Li S, Hesse F, Riechers SP, Russ J, Nicoletti C, Boeddrich A, Wiglenda T, Haenig C, ... ... Bates GP, et al. Systematic interaction network filtering identifies CRMP1 as a novel suppressor of huntingtin misfolding and neurotoxicity. Genome Research. 25: 701-13. PMID 25908449 DOI: 10.1101/Gr.182444.114 |
0.404 |
|
| 2015 |
Mielcarek M, Toczek M, Smeets CJ, Franklin SA, Bondulich MK, Jolinon N, Muller T, Ahmed M, Dick JR, Piotrowska I, Greensmith L, Smolenski RT, Bates GP. HDAC4-myogenin axis as an important marker of HD-related skeletal muscle atrophy. Plos Genetics. 11: e1005021. PMID 25748626 DOI: 10.1371/Journal.Pgen.1005021 |
0.371 |
|
| 2014 |
Träger U, Andre R, Magnusson-Lind A, Miller JR, Connolly C, Weiss A, Grueninger S, Silajdži? E, Smith DL, Leavitt BR, Bates GP, Björkqvist M, Tabrizi SJ. Characterisation of immune cell function in fragment and full-length Huntington's disease mouse models. Neurobiology of Disease. 73: 388-398. PMID 25447230 DOI: 10.1016/j.nbd.2014.10.012 |
0.424 |
|
| 2014 |
Neueder A, Bates GP. A common gene expression signature in Huntington's disease patient brain regions. Bmc Medical Genomics. 7: 60. PMID 25358814 DOI: 10.1186/s12920-014-0060-2 |
0.462 |
|
| 2014 |
Mielcarek M, Bondulich MK, Inuabasi L, Franklin SA, Muller T, Bates GP. The Huntington's disease-related cardiomyopathy prevents a hypertrophic response in the R6/2 mouse model. Plos One. 9: e108961. PMID 25268775 DOI: 10.1371/journal.pone.0108961 |
0.463 |
|
| 2014 |
Corrochano S, Renna M, Osborne G, Carter S, Stewart M, May J, Bates GP, Brown SD, Rubinsztein DC, Acevedo-Arozena A. Reducing Igf-1r levels leads to paradoxical and sexually dimorphic effects in HD mice. Plos One. 9: e105595. PMID 25140802 DOI: 10.1371/journal.pone.0105595 |
0.394 |
|
| 2014 |
Mielcarek M, Inuabasi L, Bondulich MK, Muller T, Osborne GF, Franklin SA, Smith DL, Neueder A, Rosinski J, Rattray I, Protti A, Bates GP. Dysfunction of the CNS-heart axis in mouse models of Huntington's disease. Plos Genetics. 10: e1004550. PMID 25101683 DOI: 10.1371/Journal.Pgen.1004550 |
0.476 |
|
| 2014 |
Menalled LB, Kudwa AE, Oakeshott S, Farrar A, Paterson N, Filippov I, Miller S, Kwan M, Olsen M, Beltran J, Torello J, Fitzpatrick J, Mushlin R, Cox K, McConnell K, ... ... Bates GP, et al. Genetic deletion of transglutaminase 2 does not rescue the phenotypic deficits observed in R6/2 and zQ175 mouse models of Huntington's disease. Plos One. 9: e99520. PMID 24955833 DOI: 10.1371/Journal.Pone.0099520 |
0.398 |
|
| 2014 |
Beaumont V, Park L, Rassoulpour A, Dijkman U, Heikkinen T, Lehtimaki K, Kontkanen O, Al Nackkash R, Bates GP, Gleyzes M, Steidl E, Ramboz S, Murphy C, Beconi MG, Dominguez C, et al. The PDE1/5 Inhibitor SCH-51866 Does Not Modify Disease Progression in the R6/2 Mouse Model of Huntington's Disease. Plos Currents. 6. PMID 24558637 DOI: 10.1371/currents.hd.3304e87e460b4bb0dc519a29f4deccca |
0.453 |
|
| 2014 |
Carnemolla A, Labbadia JP, Lazell H, Neueder A, Moussaoui S, Bates GP. Contesting the dogma of an age-related heat shock response impairment: implications for cardiac-specific age-related disorders. Human Molecular Genetics. 23: 3641-56. PMID 24556212 DOI: 10.1093/hmg/ddu073 |
0.335 |
|
| 2014 |
Träger U, Andre R, Lahiri N, Magnusson-Lind A, Weiss A, Grueninger S, McKinnon C, Sirinathsinghji E, Kahlon S, Pfister EL, Moser R, Hummerich H, Antoniou M, Bates GP, Luthi-Carter R, et al. HTT-lowering reverses Huntington's disease immune dysfunction caused by NFκB pathway dysregulation. Brain : a Journal of Neurology. 137: 819-33. PMID 24459107 DOI: 10.1093/brain/awt355 |
0.447 |
|
| 2014 |
Schipper-Krom S, Juenemann K, Jansen AH, Wiemhoefer A, van den Nieuwendijk R, Smith DL, Hink MA, Bates GP, Overkleeft H, Ovaa H, Reits E. Dynamic recruitment of active proteasomes into polyglutamine initiated inclusion bodies. Febs Letters. 588: 151-9. PMID 24291262 DOI: 10.1016/J.Febslet.2013.11.023 |
0.405 |
|
| 2014 |
Mielcarek M, Inuabasi L, Bondulich M, Muller T, Osborne G, Franklin S, Smith D, Neuder A, Rosinski J, Rattray I, Protti A, Bates G. B44 The Cns-heart Axis Is A Source Of Cardiac Dysfunction In Mouse Models Of Huntington's Disease Journal of Neurology, Neurosurgery & Psychiatry. 85: A24-A24. DOI: 10.1136/Jnnp-2014-309032.72 |
0.428 |
|
| 2013 |
Rattray I, Smith EJ, Crum WR, Walker TA, Gale R, Bates GP, Modo M. Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/1 mouse model of Huntington's disease. Plos One. 8: e84726. PMID 24367693 DOI: 10.1371/journal.pone.0084726 |
0.46 |
|
| 2013 |
Mielcarek M, Landles C, Weiss A, Bradaia A, Seredenina T, Inuabasi L, Osborne GF, Wadel K, Touller C, Butler R, Robertson J, Franklin SA, Smith DL, Park L, Marks PA, ... ... Bates GP, et al. HDAC4 reduction: a novel therapeutic strategy to target cytoplasmic huntingtin and ameliorate neurodegeneration. Plos Biology. 11: e1001717. PMID 24302884 DOI: 10.1371/Journal.Pbio.1001717 |
0.457 |
|
| 2013 |
Mielcarek M, Seredenina T, Stokes MP, Osborne GF, Landles C, Inuabasi L, Franklin SA, Silva JC, Luthi-Carter R, Beaumont V, Bates GP. HDAC4 does not act as a protein deacetylase in the postnatal murine brain in vivo. Plos One. 8: e80849. PMID 24278330 DOI: 10.1371/journal.pone.0080849 |
0.362 |
|
| 2013 |
Gipson TA, Neueder A, Wexler NS, Bates GP, Housman D. Aberrantly spliced HTT, a new player in Huntington's disease pathogenesis. Rna Biology. 10: 1647-52. PMID 24256709 DOI: 10.4161/rna.26706 |
0.489 |
|
| 2013 |
Vashishtha M, Ng CW, Yildirim F, Gipson TA, Kratter IH, Bodai L, Song W, Lau A, Labadorf A, Vogel-Ciernia A, Troncosco J, Ross CA, Bates GP, Krainc D, Sadri-Vakili G, et al. Targeting H3K4 trimethylation in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America. 110: E3027-36. PMID 23872847 DOI: 10.1073/Pnas.1311323110 |
0.481 |
|
| 2013 |
O'Rourke JG, Gareau JR, Ochaba J, Song W, Raskó T, Reverter D, Lee J, Monteys AM, Pallos J, Mee L, Vashishtha M, Apostol BL, Nicholson TP, Illes K, Zhu YZ, ... ... Bates GP, et al. SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation. Cell Reports. 4: 362-75. PMID 23871671 DOI: 10.1016/J.Celrep.2013.06.034 |
0.402 |
|
| 2013 |
Rattray I, Smith E, Gale R, Matsumoto K, Bates GP, Modo M. Correlations of behavioral deficits with brain pathology assessed through longitudinal MRI and histopathology in the R6/2 mouse model of HD. Plos One. 8: e60012. PMID 23593159 DOI: 10.1371/journal.pone.0060012 |
0.444 |
|
| 2013 |
Sathasivam K, Neueder A, Gipson TA, Landles C, Benjamin AC, Bondulich MK, Smith DL, Faull RL, Roos RA, Howland D, Detloff PJ, Housman DE, Bates GP. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America. 110: 2366-70. PMID 23341618 DOI: 10.1073/Pnas.1221891110 |
0.474 |
|
| 2013 |
Horne EA, Coy J, Swinney K, Fung S, Cherry AE, Marrs WR, Naydenov AV, Lin YH, Sun X, Keene CD, Grouzmann E, Muchowski P, Bates GP, Mackie K, Stella N. Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models. The European Journal of Neuroscience. 37: 429-40. PMID 23167744 DOI: 10.1111/Ejn.12045 |
0.415 |
|
| 2012 |
Weiss A, Träger U, Wild EJ, Grueninger S, Farmer R, Landles C, Scahill RI, Lahiri N, Haider S, Macdonald D, Frost C, Bates GP, Bilbe G, Kuhn R, Andre R, et al. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression. The Journal of Clinical Investigation. 122: 3731-6. PMID 22996692 DOI: 10.1172/Jci64565 |
0.452 |
|
| 2012 |
Marcellin D, Abramowski D, Young D, Richter J, Weiss A, Marcel A, Maassen J, Kauffmann M, Bibel M, Shimshek DR, Faull RL, Bates GP, Kuhn RR, Van der Putten PH, Schmid P, et al. Fragments of HdhQ150 mutant huntingtin form a soluble oligomer pool that declines with aggregate deposition upon aging. Plos One. 7: e44457. PMID 22984513 DOI: 10.1371/journal.pone.0044457 |
0.428 |
|
| 2012 |
Beconi M, Aziz O, Matthews K, Moumné L, O'Connell C, Yates D, Clifton S, Pett H, Vann J, Crowley L, Haughan AF, Smith DL, Woodman B, Bates GP, Brookfield F, et al. Oral administration of the pimelic diphenylamide HDAC inhibitor HDACi 4b is unsuitable for chronic inhibition of HDAC activity in the CNS in vivo. Plos One. 7: e44498. PMID 22973455 DOI: 10.1371/journal.pone.0044498 |
0.392 |
|
| 2012 |
Landles C, Weiss A, Franklin S, Howland D, Bates G. Caspase-6 does not contribute to the proteolysis of mutant huntingtin in the HdhQ150 knock-in mouse model of Huntington's disease. Plos Currents. 4: e4fd085bfc9973. PMID 22919566 DOI: 10.1371/4fd085bfc9973 |
0.501 |
|
| 2012 |
El-Akabawy G, Rattray I, Johansson SM, Gale R, Bates G, Modo M. Implantation of undifferentiated and pre-differentiated human neural stem cells in the R6/2 transgenic mouse model of Huntington's disease. Bmc Neuroscience. 13: 97. PMID 22876937 DOI: 10.1186/1471-2202-13-97 |
0.413 |
|
| 2012 |
Bobrowska A, Donmez G, Weiss A, Guarente L, Bates G. SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo. Plos One. 7: e34805. PMID 22511966 DOI: 10.1371/Journal.Pone.0034805 |
0.521 |
|
| 2012 |
Labbadia J, Novoselov SS, Bett JS, Weiss A, Paganetti P, Bates GP, Cheetham ME. Suppression of protein aggregation by chaperone modification of high molecular weight complexes. Brain : a Journal of Neurology. 135: 1180-96. PMID 22396390 DOI: 10.1093/brain/aws022 |
0.499 |
|
| 2012 |
Baldo B, Paganetti P, Grueninger S, Marcellin D, Kaltenbach LS, Lo DC, Semmelroth M, Zivanovic A, Abramowski D, Smith D, Lotz GP, Bates GP, Weiss A. TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease. Chemistry & Biology. 19: 264-75. PMID 22365609 DOI: 10.1016/j.chembiol.2011.12.020 |
0.489 |
|
| 2012 |
Moumné L, Campbell K, Howland D, Ouyang Y, Bates GP. Genetic knock-down of HDAC3 does not modify disease-related phenotypes in a mouse model of Huntington's disease. Plos One. 7: e31080. PMID 22347433 DOI: 10.1371/journal.pone.0031080 |
0.479 |
|
| 2012 |
Träger U, André R, Lahiri N, Magnusson A, Pfister E, Weiss A, Grüninger S, Antoniou M, Bates G, Muchowski P, Björkqvist M, Ostroff G, Aronin N, Tabrizi S. B23 Immune dysfunction in HD human myeloid cells is caused by NFκB pathway dysregulation and is reversed by lowering HTT levels Journal of Neurology, Neurosurgery & Psychiatry. 83: A12.3-A13. DOI: 10.1136/Jnnp-2012-303524.39 |
0.359 |
|
| 2012 |
Mielcarek M, Landles C, Weiss A, Bradaia A, Seredenina T, Inuabasi L, Wadel K, Touller C, Butler R, Robertson J, Franklin S, Smith D, Park L, Marks P, Wanker E, ... ... Bates G, et al. A12 HDAC4 interacts with huntington and HDAC4 reduction decreases cytoplamsic aggregation and rescues synaptic dysfunction in HD mouse models Journal of Neurology, Neurosurgery, and Psychiatry. 83. DOI: 10.1136/Jnnp-2012-303524.12 |
0.477 |
|
| 2011 |
Mielcarek M, Benn CL, Franklin SA, Smith DL, Woodman B, Marks PA, Bates GP. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. Plos One. 6: e27746. PMID 22140466 DOI: 10.1371/journal.pone.0027746 |
0.765 |
|
| 2011 |
Labbadia J, Cunliffe H, Weiss A, Katsyuba E, Sathasivam K, Seredenina T, Woodman B, Moussaoui S, Frentzel S, Luthi-Carter R, Paganetti P, Bates GP. Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease. The Journal of Clinical Investigation. 121: 3306-19. PMID 21785217 DOI: 10.1172/JCI57413 |
0.499 |
|
| 2011 |
Bobrowska A, Paganetti P, Matthias P, Bates GP. Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease. Plos One. 6: e20696. PMID 21677773 DOI: 10.1371/journal.pone.0020696 |
0.518 |
|
| 2011 |
van der Burg JM, Winqvist A, Aziz NA, Maat-Schieman ML, Roos RA, Bates GP, Brundin P, Björkqvist M, Wierup N. Gastrointestinal dysfunction contributes to weight loss in Huntington's disease mice. Neurobiology of Disease. 44: 1-8. PMID 21624468 DOI: 10.1016/J.Nbd.2011.05.006 |
0.413 |
|
| 2011 |
Taylor DM, Balabadra U, Xiang Z, Woodman B, Meade S, Amore A, Maxwell MM, Reeves S, Bates GP, Luthi-Carter R, Lowden PA, Kazantsev AG. A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. Acs Chemical Biology. 6: 540-6. PMID 21370928 DOI: 10.1021/cb100376q |
0.379 |
|
| 2011 |
Munoz-Sanjuan I, Bates GP. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. The Journal of Clinical Investigation. 121: 476-83. PMID 21285520 DOI: 10.1172/JCI45364 |
0.421 |
|
| 2010 |
Luthi-Carter R, Taylor DM, Pallos J, Lambert E, Amore A, Parker A, Moffitt H, Smith DL, Runne H, Gokce O, Kuhn A, Xiang Z, Maxwell MM, Reeves SA, Bates GP, et al. SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proceedings of the National Academy of Sciences of the United States of America. 107: 7927-32. PMID 20378838 DOI: 10.1073/Pnas.1002924107 |
0.427 |
|
| 2010 |
Crittenden JR, Dunn DE, Merali FI, Woodman B, Yim M, Borkowska AE, Frosch MP, Bates GP, Housman DE, Lo DC, Graybiel AM. CalDAG-GEFI down-regulation in the striatum as a neuroprotective change in Huntington's disease. Human Molecular Genetics. 19: 1756-65. PMID 20147317 DOI: 10.1093/Hmg/Ddq055 |
0.532 |
|
| 2010 |
Landles C, Sathasivam K, Weiss A, Woodman B, Moffitt H, Finkbeiner S, Sun B, Gafni J, Ellerby LM, Trottier Y, Richards WG, Osmand A, Paganetti P, Bates GP. Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington disease. The Journal of Biological Chemistry. 285: 8808-23. PMID 20086007 DOI: 10.1074/Jbc.M109.075028 |
0.444 |
|
| 2010 |
Sathasivam K, Lane A, Legleiter J, Warley A, Woodman B, Finkbeiner S, Paganetti P, Muchowski PJ, Wilson S, Bates GP. Identical oligomeric and fibrillar structures captured from the brains of R6/2 and knock-in mouse models of Huntington's disease. Human Molecular Genetics. 19: 65-78. PMID 19825844 DOI: 10.1093/Hmg/Ddp467 |
0.464 |
|
| 2010 |
André R, Schure U, Magnusson A, Lahiri N, Smith D, Lowdell MW, Bates G, Bjorkqvist M, Tabrizi SJ. A17 Myeloid cell function in mouse models of Huntington's disease Journal of Neurology, Neurosurgery & Psychiatry. 81: A5.4-A6. DOI: 10.1136/jnnp.2010.222570.17 |
0.381 |
|
| 2010 |
Taylor D, Pallos J, Lambert E, Amore A, Parker A, Moffitt H, Smith D, Runne H, Gokce O, Kuhn A, Xiang Z, Maxwell M, Reeves S, Bates G, Néri C, et al. A10 SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis Journal of Neurology, Neurosurgery, and Psychiatry. 81. DOI: 10.1136/Jnnp.2010.222570.10 |
0.418 |
|
| 2009 |
Thompson LM, Aiken CT, Kaltenbach LS, Agrawal N, Illes K, Khoshnan A, Martinez-Vincente M, Arrasate M, O'Rourke JG, Khashwji H, Lukacsovich T, Zhu YZ, Lau AL, Massey A, Hayden MR, ... ... Bates G, et al. IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. The Journal of Cell Biology. 187: 1083-99. PMID 20026656 DOI: 10.1083/Jcb.200909067 |
0.435 |
|
| 2009 |
Moffitt H, McPhail GD, Woodman B, Hobbs C, Bates GP. Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. Plos One. 4: e8025. PMID 19956633 DOI: 10.1371/journal.pone.0008025 |
0.518 |
|
| 2009 |
Bett JS, Benn CL, Ryu KY, Kopito RR, Bates GP. The polyubiquitin Ubc gene modulates histone H2A monoubiquitylation in the R6/2 mouse model of Huntington's disease. Journal of Cellular and Molecular Medicine. 13: 2645-57. PMID 19602042 DOI: 10.1111/j.1582-4934.2008.00543.x |
0.783 |
|
| 2009 |
Benn CL, Butler R, Mariner L, Nixon J, Moffitt H, Mielcarek M, Woodman B, Bates GP. Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease. Plos One. 4: e5747. PMID 19484127 DOI: 10.1371/journal.pone.0005747 |
0.769 |
|
| 2009 |
Bett JS, Cook C, Petrucelli L, Bates GP. The ubiquitin-proteasome reporter GFPu does not accumulate in neurons of the R6/2 transgenic mouse model of Huntington's disease. Plos One. 4: e5128. PMID 19352500 DOI: 10.1371/Journal.Pone.0005128 |
0.513 |
|
| 2009 |
Zabel C, Mao L, Woodman B, Rohe M, Wacker MA, Kläre Y, Koppelstätter A, Nebrich G, Klein O, Grams S, Strand A, Luthi-Carter R, Hartl D, Klose J, Bates GP. A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for huntington disease. Molecular & Cellular Proteomics : McP. 8: 720-34. PMID 19043139 DOI: 10.1074/mcp.M800277-MCP200 |
0.433 |
|
| 2009 |
Martin B, Golden E, Carlson OD, Pistell P, Zhou J, Kim W, Frank BP, Thomas S, Chadwick WA, Greig NH, Bates GP, Sathasivam K, Bernier M, Maudsley S, Mattson MP, et al. Exendin-4 improves glycemic control, ameliorates brain and pancreatic pathologies, and extends survival in a mouse model of Huntington's disease. Diabetes. 58: 318-28. PMID 18984744 DOI: 10.2337/Db08-0799 |
0.499 |
|
| 2008 |
Benn CL, Fox H, Bates GP. Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease. Molecular Neurodegeneration. 3: 17. PMID 18954449 DOI: 10.1186/1750-1326-3-17 |
0.726 |
|
| 2008 |
Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, ... ... Bates GP, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. The Journal of Experimental Medicine. 205: 1869-77. PMID 18625748 DOI: 10.1084/Jem.20080178 |
0.726 |
|
| 2008 |
Gonitel R, Moffitt H, Sathasivam K, Woodman B, Detloff PJ, Faull RL, Bates GP. DNA instability in postmitotic neurons. Proceedings of the National Academy of Sciences of the United States of America. 105: 3467-72. PMID 18299573 DOI: 10.1073/Pnas.0800048105 |
0.376 |
|
| 2008 |
Weiss A, Klein C, Woodman B, Sathasivam K, Bibel M, Régulier E, Bates GP, Paganetti P. Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. Journal of Neurochemistry. 104: 846-58. PMID 17986219 DOI: 10.1111/j.1471-4159.2007.05032.x |
0.491 |
|
| 2008 |
van der Burg JM, Bacos K, Wood NI, Lindqvist A, Wierup N, Woodman B, Wamsteeker JI, Smith R, Deierborg T, Kuhar MJ, Bates GP, Mulder H, Erlanson-Albertsson C, Morton AJ, Brundin P, et al. Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiology of Disease. 29: 41-51. PMID 17920283 DOI: 10.1016/J.Nbd.2007.07.029 |
0.36 |
|
| 2008 |
Wild EJ, Björkqvist M, Thiele J, Silvestroni A, Soulet D, Magnusson A, Benn CL, Woodman B, André R, Landles C, Pouladi MA, Hayden MR, Khalili-Shirazi A, Lowdell MW, Brundin P, ... Bates GP, et al. P3-377: A novel pathogenic pathway of immune activation detectable before cinical onset in Huntington's disease Alzheimer's & Dementia. 4: T632-T632. DOI: 10.1016/J.Jalz.2008.05.1947 |
0.706 |
|
| 2007 |
Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, Becker CH, Bates GP, Schulman H, Kopito RR. Global changes to the ubiquitin system in Huntington's disease. Nature. 448: 704-8. PMID 17687326 DOI: 10.1038/nature06022 |
0.53 |
|
| 2007 |
Dalrymple A, Wild EJ, Joubert R, Sathasivam K, Björkqvist M, Petersén A, Jackson GS, Isaacs JD, Kristiansen M, Bates GP, Leavitt BR, Keir G, Ward M, Tabrizi SJ. Proteomic profiling of plasma in Huntington's disease reveals neuroinflammatory activation and biomarker candidates. Journal of Proteome Research. 6: 2833-40. PMID 17552550 DOI: 10.1021/Pr0700753 |
0.411 |
|
| 2007 |
Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, ... ... Bates GP, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Human Molecular Genetics. 16: 1845-61. PMID 17519223 DOI: 10.1093/Hmg/Ddm133 |
0.509 |
|
| 2007 |
Zourlidou A, Gidalevitz T, Kristiansen M, Landles C, Woodman B, Wells DJ, Latchman DS, de Belleroche J, Tabrizi SJ, Morimoto RI, Bates GP. Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation. Human Molecular Genetics. 16: 1078-90. PMID 17360721 DOI: 10.1093/Hmg/Ddm057 |
0.436 |
|
| 2007 |
Woodman B, Butler R, Landles C, Lupton MK, Tse J, Hockly E, Moffitt H, Sathasivam K, Bates GP. The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Research Bulletin. 72: 83-97. PMID 17352931 DOI: 10.1016/j.brainresbull.2006.11.004 |
0.473 |
|
| 2006 |
Butler R, Bates GP. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nature Reviews. Neuroscience. 7: 784-96. PMID 16988654 DOI: 10.1038/nrn1989 |
0.453 |
|
| 2006 |
Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, Slow EJ, Wheeler VC, Woodman B, Schwarcz R. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiology of Disease. 23: 190-7. PMID 16697652 DOI: 10.1016/J.Nbd.2006.02.011 |
0.444 |
|
| 2006 |
Tarditi A, Camurri A, Varani K, Borea PA, Woodman B, Bates G, Cattaneo E, Abbracchio MP. Early and transient alteration of adenosine A2A receptor signaling in a mouse model of Huntington disease. Neurobiology of Disease. 23: 44-53. PMID 16651003 DOI: 10.1016/J.Nbd.2006.01.014 |
0.368 |
|
| 2006 |
Björkqvist M, Petersén A, Bacos K, Isaacs J, Norlén P, Gil J, Popovic N, Sundler F, Bates GP, Tabrizi SJ, Brundin P, Mulder H. Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. Human Molecular Genetics. 15: 1713-21. PMID 16613897 DOI: 10.1093/Hmg/Ddl094 |
0.448 |
|
| 2006 |
Bates GP. BIOMEDICINE: One Misfolded Protein Allows Others to Sneak By. Science (New York, N.Y.). 311: 1385-6. PMID 16527959 DOI: 10.1126/science.1125246 |
0.355 |
|
| 2006 |
Tsang TM, Woodman B, McLoughlin GA, Griffin JL, Tabrizi SJ, Bates GP, Holmes E. Metabolic characterization of the R6/2 transgenic mouse model of Huntington's disease by high-resolution MAS 1H NMR spectroscopy. Journal of Proteome Research. 5: 483-92. PMID 16512662 DOI: 10.1021/pr050244o |
0.426 |
|
| 2006 |
Bates GP, Gonitel R. Mouse models of triplet repeat diseases. Molecular Biotechnology. 32: 147-58. PMID 16444016 DOI: 10.1385/MB:32:2:147 |
0.403 |
|
| 2006 |
Bett JS, Goellner GM, Woodman B, Pratt G, Rechsteiner M, Bates GP. Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REGgamma as a therapeutic target. Human Molecular Genetics. 15: 33-44. PMID 16311253 DOI: 10.1093/Hmg/Ddi423 |
0.494 |
|
| 2006 |
Hockly E, Tse J, Barker AL, Moolman DL, Beunard JL, Revington AP, Holt K, Sunshine S, Moffitt H, Sathasivam K, Woodman B, Wanker EE, Lowden PA, Bates GP. Evaluation of the benzothiazole aggregation inhibitors riluzole and PGL-135 as therapeutics for Huntington's disease. Neurobiology of Disease. 21: 228-36. PMID 16111888 DOI: 10.1016/j.nbd.2005.07.007 |
0.469 |
|
| 2005 |
Henley SM, Bates GP, Tabrizi SJ. Biomarkers for neurodegenerative diseases. Current Opinion in Neurology. 18: 698-705. PMID 16280682 DOI: 10.1097/01.wco.0000186842.51129.cb |
0.384 |
|
| 2005 |
Valenza M, Rigamonti D, Goffredo D, Zuccato C, Fenu S, Jamot L, Strand A, Tarditi A, Woodman B, Racchi M, Mariotti C, Di Donato S, Corsini A, Bates G, Pruss R, et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 9932-9. PMID 16251441 DOI: 10.1523/Jneurosci.3355-05.2005 |
0.471 |
|
| 2005 |
Papalexi E, Persson A, Björkqvist M, Petersén A, Woodman B, Bates GP, Sundler F, Mulder H, Brundin P, Popovic N. Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease. The European Journal of Neuroscience. 22: 1541-6. PMID 16190907 DOI: 10.1111/J.1460-9568.2005.04324.X |
0.408 |
|
| 2005 |
Benn CL, Landles C, Li H, Strand AD, Woodman B, Sathasivam K, Li SH, Ghazi-Noori S, Hockly E, Faruque SM, Cha JH, Sharpe PT, Olson JM, Li XJ, Bates GP. Contribution of nuclear and extranuclear polyQ to neurological phenotypes in mouse models of Huntington's disease. Human Molecular Genetics. 14: 3065-78. PMID 16183657 DOI: 10.1093/Hmg/Ddi340 |
0.756 |
|
| 2005 |
Bates GP. History of genetic disease: the molecular genetics of Huntington disease - a history. Nature Reviews. Genetics. 6: 766-73. PMID 16136077 DOI: 10.1038/nrg1686 |
0.415 |
|
| 2005 |
Smith R, Petersén A, Bates GP, Brundin P, Li JY. Depletion of rabphilin 3A in a transgenic mouse model (R6/1) of Huntington's disease, a possible culprit in synaptic dysfunction. Neurobiology of Disease. 20: 673-84. PMID 15967669 DOI: 10.1016/J.Nbd.2005.05.008 |
0.432 |
|
| 2005 |
Miller TW, Zhou C, Gines S, MacDonald ME, Mazarakis ND, Bates GP, Huston JS, Messer A. A human single-chain Fv intrabody preferentially targets amino-terminal Huntingtin's fragments in striatal models of Huntington's disease. Neurobiology of Disease. 19: 47-56. PMID 15837560 DOI: 10.1016/J.Nbd.2004.11.003 |
0.415 |
|
| 2005 |
Cornett J, Cao F, Wang CE, Ross CA, Bates GP, Li SH, Li XJ. Polyglutamine expansion of huntingtin impairs its nuclear export. Nature Genetics. 37: 198-204. PMID 15654337 DOI: 10.1038/Ng1503 |
0.375 |
|
| 2005 |
Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M, Washington SL, Maxwell MM, Marsh JL, Thompson LM, Wanker EE, Young AB, Housman DE, Bates GP, Sherman MY, et al. A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proceedings of the National Academy of Sciences of the United States of America. 102: 892-7. PMID 15642944 DOI: 10.1073/pnas.0408936102 |
0.455 |
|
| 2005 |
Hultschig C, Zabel C, Blüggel M, Bates GP, Meyer HE, Kloska S, Lehrach H, Schuchhardt J, Kleinjung F, Klose J. Combined Proteome and Transcriptome Analysis of Alterations in the Mouse Brain Caused by Huntington?s Disease Gbm Annual Fall Meeting Berlin/Potsdam 2005. 2005. DOI: 10.1240/SAV_GBM_2005_H_001163 |
0.336 |
|
| 2004 |
Landles C, Bates GP. Huntingtin and the molecular pathogenesis of Huntington's disease. Fourth in molecular medicine review series. Embo Reports. 5: 958-63. PMID 15459747 DOI: 10.1038/sj.embor.7400250 |
0.474 |
|
| 2004 |
Smith DL, Bates GP. Monitoring aggregate formation in organotypic slice cultures from transgenic mice. Methods in Molecular Biology (Clifton, N.J.). 277: 161-71. PMID 15201455 DOI: 10.1385/1-59259-804-8:161 |
0.451 |
|
| 2004 |
Bates GP, Hay DG. Mouse models of triplet repeat diseases. Methods in Molecular Biology (Clifton, N.J.). 277: 3-15. PMID 15201445 DOI: 10.1385/1-59259-804-8:003 |
0.417 |
|
| 2004 |
Hay DG, Sathasivam K, Tobaben S, Stahl B, Marber M, Mestril R, Mahal A, Smith DL, Woodman B, Bates GP. Progressive decrease in chaperone protein levels in a mouse model of Huntington's disease and induction of stress proteins as a therapeutic approach. Human Molecular Genetics. 13: 1389-405. PMID 15115766 DOI: 10.1093/Hmg/Ddh144 |
0.471 |
|
| 2003 |
Luthi-Carter R, Apostol BL, Dunah AW, DeJohn MM, Farrell LA, Bates GP, Young AB, Standaert DG, Thompson LM, Cha JH. Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation. Neurobiology of Disease. 14: 624-36. PMID 14678777 DOI: 10.1016/j.nbd.2003.08.024 |
0.328 |
|
| 2003 |
Hockly E, Woodman B, Mahal A, Lewis CM, Bates G. Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Research Bulletin. 61: 469-79. PMID 13679245 DOI: 10.1016/S0361-9230(03)00185-0 |
0.379 |
|
| 2003 |
Orth M, Cooper JM, Bates GP, Schapira AH. Inclusion formation in Huntington's disease R6/2 mouse muscle cultures. Journal of Neurochemistry. 87: 1-6. PMID 12969246 DOI: 10.1046/j.1471-4159.2003.02009.x |
0.452 |
|
| 2003 |
Gourfinkel-An I, Parain K, Hartmann A, Mangiarini L, Brice A, Bates G, Hirsch EC. Changes in GAD67 mRNA expression evidenced by in situ hybridization in the brain of R6/2 transgenic mice. Journal of Neurochemistry. 86: 1369-1378. PMID 12950446 DOI: 10.1046/J.1471-4159.2003.01916.X |
0.49 |
|
| 2003 |
Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, Lowden PA, Bates GP, Hockly E. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Annals of Neurology. 54: 186-96. PMID 12891671 DOI: 10.1002/ana.10614 |
0.465 |
|
| 2003 |
Bates GP, Hockly E. Experimental therapeutics in Huntington's disease: are models useful for therapeutic trials? Current Opinion in Neurology. 16: 465-70. PMID 12869804 DOI: 10.1097/01.wco.0000084223.82329.bb |
0.407 |
|
| 2003 |
Bates G. Huntingtin aggregation and toxicity in Huntington's disease. The Lancet. 361: 1642-1644. PMID 12747895 DOI: 10.1016/S0140-6736(03)13304-1 |
0.457 |
|
| 2003 |
Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, ... Bates GP, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 100: 2041-6. PMID 12576549 DOI: 10.1073/pnas.0437870100 |
0.477 |
|
| 2002 |
Liévens JC, Woodman B, Mahal A, Bates GP. Abnormal phosphorylation of synapsin I predicts a neuronal transmission impairment in the R6/2 Huntington's disease transgenic mice. Molecular and Cellular Neurosciences. 20: 638-48. PMID 12213445 DOI: 10.1006/mcne.2002.1152 |
0.447 |
|
| 2002 |
Zabel C, Chamrad DC, Priller J, Woodman B, Meyer HE, Bates GP, Klose J. Alterations in the mouse and human proteome caused by Huntington's disease. Molecular & Cellular Proteomics : McP. 1: 366-75. PMID 12118078 DOI: 10.1074/Mcp.M200016-Mcp200 |
0.474 |
|
| 2002 |
Peters PJ, Ning K, Palacios F, Boshans RL, Kazantsev A, Thompson LM, Woodman B, Bates GP, D'Souza-Schorey C. Arfaptin 2 regulates the aggregation of mutant huntingtin protein. Nature Cell Biology. 4: 240-5. PMID 11854752 DOI: 10.1038/Ncb761 |
0.443 |
|
| 2002 |
Hockly E, Cordery PM, Woodman B, Mahal A, van Dellen A, Blakemore C, Lewis CM, Hannan AJ, Bates GP. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Annals of Neurology. 51: 235-42. PMID 11835380 DOI: 10.1002/Ana.10094 |
0.52 |
|
| 2001 |
Smith DL, Portier R, Woodman B, Hockly E, Mahal A, Klunk WE, Li XJ, Wanker E, Murray KD, Bates GP. Inhibition of polyglutamine aggregation in R6/2 HD brain slices-complex dose-response profiles. Neurobiology of Disease. 8: 1017-26. PMID 11741397 DOI: 10.1006/nbdi.2001.0438 |
0.442 |
|
| 2001 |
Sathasivam K, Woodman B, Mahal A, Bertaux F, Wanker EE, Shima DT, Bates GP. Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients. Human Molecular Genetics. 10: 2425-35. PMID 11689489 DOI: 10.1093/Hmg/10.21.2425 |
0.481 |
|
| 2001 |
Bates GP. Huntington's disease. Exploiting expression. Nature. 413: 691, 693-4. PMID 11607014 DOI: 10.1038/35099656 |
0.425 |
|
| 2001 |
Liévens JC, Woodman B, Mahal A, Spasic-Boscovic O, Samuel D, Kerkerian-Le Goff L, Bates GP. Impaired glutamate uptake in the R6 Huntington's disease transgenic mice. Neurobiology of Disease. 8: 807-21. PMID 11592850 DOI: 10.1006/nbdi.2001.0430 |
0.437 |
|
| 2001 |
Hansson O, Castilho RF, Korhonen L, Lindholm D, Bates GP, Brundin P. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. Journal of Neurochemistry. 78: 694-703. PMID 11520890 DOI: 10.1046/J.1471-4159.2001.00482.X |
0.419 |
|
| 2001 |
Kusakabe M, Mangiarini L, Laywell ED, Bates GP, Yoshiki A, Hiraiwa N, Inoue J, Steindler DA. Loss of cortical and thalamic neuronal tenascin-C expression in a transgenic mouse expressing exon 1 of the human Huntington disease gene. The Journal of Comparative Neurology. 430: 485-500. PMID 11169482 DOI: 10.1002/1096-9861(20010219)430:4<485::Aid-Cne1045>3.0.Co;2-6 |
0.446 |
|
| 2000 |
McGowan DP, van Roon-Mom W, Holloway H, Bates GP, Mangiarini L, Cooper GJ, Faull RL, Snell RG. Amyloid-like inclusions in Huntington's disease. Neuroscience. 100: 677-80. PMID 11036200 DOI: 10.1016/S0306-4522(00)00391-2 |
0.502 |
|
| 2000 |
Bates G, Eberwine J. Hunting in the calm before the storm Nature Genetics. 25: 365-366. PMID 10932169 DOI: 10.1038/78020 |
0.364 |
|
| 2000 |
Turmaine M, Raza A, Mahal A, Mangiarini L, Bates GP, Davies SW. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America. 97: 8093-7. PMID 10869421 DOI: 10.1073/pnas.110078997 |
0.46 |
|
| 2000 |
Murphy KP, Carter RJ, Lione LA, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 20: 5115-23. PMID 10864968 DOI: 10.1523/Jneurosci.20-13-05115.2000 |
0.387 |
|
| 2000 |
Steffan JS, Kazantsev A, Spasic-Boskovic O, Greenwald M, Zhu YZ, Gohler H, Wanker EE, Bates GP, Housman DE, Thompson LM. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proceedings of the National Academy of Sciences of the United States of America. 97: 6763-8. PMID 10823891 DOI: 10.1073/pnas.100110097 |
0.414 |
|
| 2000 |
Bates G. Huntington's disease. In reverse gear. Nature. 404: 944-945. PMID 10801109 DOI: 10.1038/35010254 |
0.44 |
|
| 2000 |
Benn C, Hay D, Hockly E, Gonitel R, Lievens J, Mahal A, Sathasivam K, Spasic-Boskovic O, Smith D, Woodman B, Bates G. The Molecular Basis of Huntington's Disease and Polyglutamine Disorders Biochemical Society Transactions. 28: A125-A125. DOI: 10.1042/BST028A125C |
0.378 |
|
| 2000 |
Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AHV. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse Annals of Neurology. 47: 80-86. DOI: 10.1002/1531-8249(200001)47:1<80::AID-ANA13>3.0.CO;2-K |
0.5 |
|
| 1999 |
Kosinski CM, Cha JH, Young AB, Mangiarini L, Bates G, Schiefer J, Schwarz M. Intranuclear inclusions in subtypes of striatal neurons in Huntington's disease transgenic mice. Neuroreport. 10: 3891-6. PMID 10716229 DOI: 10.1097/00001756-199912160-00031 |
0.31 |
|
| 1999 |
Lione LA, Carter RJ, Hunt MJ, Bates GP, Morton AJ, Dunnett SB. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 19: 10428-37. PMID 10575040 DOI: 10.1523/Jneurosci.19-23-10428.1999 |
0.439 |
|
| 1999 |
Davies SW, Sathasivam K, Hobbs C, Doherty P, Mangiarini L, Scherzinger E, Wanker EE, Bates GP. Detection of polyglutamine aggregation in mouse models. Methods in Enzymology. 309: 687-701. PMID 10507055 DOI: 10.1016/S0076-6879(99)09045-X |
0.444 |
|
| 1999 |
Cha JH, Frey AS, Alsdorf SA, Kerner JA, Kosinski CM, Mangiarini L, Penney JB, Davies SW, Bates GP, Young AB. Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 354: 981-9. PMID 10434296 DOI: 10.1098/Rstb.1999.0449 |
0.398 |
|
| 1999 |
Davies SW, Turmaine M, Cozens BA, Raza AS, Mahal A, Mangiarini L, Bates GP. From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington's disease. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 354: 981-9. PMID 10434295 DOI: 10.1098/Rstb.1999.0448 |
0.517 |
|
| 1999 |
Sathasivam K, Hobbs C, Mangiarini L, Mahal A, Turmaine M, Doherty P, Davies SW, Bates GP. Transgenic models of Huntington's disease. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences. 354: 963-9. PMID 10434294 DOI: 10.1098/Rstb.1999.0447 |
0.486 |
|
| 1999 |
Li H, Li SH, Cheng AL, Mangiarini L, Bates GP, Li XJ. Ultrastructural localization and progressive formation of neuropil aggregates in Huntington's disease transgenic mice. Human Molecular Genetics. 8: 1227-36. PMID 10369868 DOI: 10.1093/Hmg/8.7.1227 |
0.408 |
|
| 1999 |
Scherzinger E, Sittler A, Schweiger K, Heiser V, Lurz R, Hasenbank R, Bates GP, Lehrach H, Wanker EE. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proceedings of the National Academy of Sciences of the United States of America. 96: 4604-9. PMID 10200309 DOI: 10.1073/Pnas.96.8.4604 |
0.42 |
|
| 1999 |
Sathasivam K, Hobbs C, Turmaine M, Mangiarini L, Mahal A, Bertaux F, Wanker EE, Doherty P, Davies SW, Bates GP. Formation of polyglutamine inclusions in non-CNS tissue. Human Molecular Genetics. 8: 813-22. PMID 10196370 DOI: 10.1093/Hmg/8.5.813 |
0.486 |
|
| 1999 |
Carter RJ, Lione LA, Humby T, Mangiarini L, Mahal A, Bates GP, Dunnett SB, Morton AJ. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 19: 3248-57. PMID 10191337 DOI: 10.1523/Jneurosci.19-08-03248.1999 |
0.426 |
|
| 1999 |
Reynolds GP, Dalton CF, Tillery CL, Mangiarini L, Davies SW, Bates GP. Brain neurotransmitter deficits in mice transgenic for the Huntington's disease mutation. Journal of Neurochemistry. 72: 1773-6. PMID 10098889 DOI: 10.1046/j.1471-4159.1999.721773.x |
0.488 |
|
| 1999 |
Mangiarini L, Sathasivam K, Bates GP. Molecular pathology of Huntington's disease: Animal models and nuclear mechanisms Neuroscientist. 5: 383-391. DOI: 10.1177/107385849900500613 |
0.486 |
|
| 1998 |
Dunnett SB, Carter RJ, Watts C, Torres EM, Mahal A, Mangiarini L, Bates G, Morton AJ. Striatal transplantation in a transgenic mouse model of Huntington's disease. Experimental Neurology. 154: 31-40. PMID 9875265 DOI: 10.1006/Exnr.1998.6926 |
0.416 |
|
| 1998 |
Sittler A, Wälter S, Wedemeyer N, Hasenbank R, Scherzinger E, Eickhoff H, Bates GP, Lehrach H, Wanker EE. SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates. Molecular Cell. 2: 427-36. PMID 9809064 DOI: 10.1016/S1097-2765(00)80142-2 |
0.432 |
|
| 1998 |
Bates GP, Mangiarini L, Davies SW. Transgenic mice in the study of polyglutamine repeat expansion diseases. Brain Pathology (Zurich, Switzerland). 8: 699-714. PMID 9804379 DOI: 10.1111/J.1750-3639.1998.Tb00196.X |
0.506 |
|
| 1998 |
Bates GP, Mangiarini L, Wanker EE, Davies SW. Polyglutamine expansion and Huntington's disease. Biochemical Society Transactions. 26: 471-5. PMID 9765898 DOI: 10.1042/Bst0260471 |
0.422 |
|
| 1998 |
File SE, Mahal A, Mangiarini L, Bates GP. Striking changes in anxiety in Huntington's disease transgenic mice. Brain Research. 805: 234-40. PMID 9733972 DOI: 10.1016/S0006-8993(98)00736-7 |
0.357 |
|
| 1998 |
Becher MW, Kotzuk JA, Sharp AH, Davies SW, Bates GP, Price DL, Ross CA. Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length. Neurobiology of Disease. 4: 387-97. PMID 9666478 DOI: 10.1006/Nbdi.1998.0168 |
0.432 |
|
| 1998 |
Cha JH, Kosinski CM, Kerner JA, Alsdorf SA, Mangiarini L, Davies SW, Penney JB, Bates GP, Young AB. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proceedings of the National Academy of Sciences of the United States of America. 95: 6480-5. PMID 9600992 DOI: 10.1073/pnas.95.11.6480 |
0.377 |
|
| 1998 |
Bertaux F, Sharp AH, Ross CA, Lehrach H, Bates GP, Wanker E. HAP1-huntingtin interactions do not contribute to the molecular pathology in Huntington's disease transgenic mice. Febs Letters. 426: 229-32. PMID 9599014 DOI: 10.1016/S0014-5793(98)00352-4 |
0.485 |
|
| 1998 |
Town M, Jean G, Cherqui S, Attard M, Forestier L, Whitmore SA, Callen DF, Gribouval O, Broyer M, Bates GP, van't Hoff W, Antignac C. A novel gene encoding an integral membrane protein is mutated in nephropathic cystinosis. Nature Genetics. 18: 319-24. PMID 9537412 DOI: 10.1038/ng0498-319 |
0.32 |
|
| 1998 |
Davies SW, Beardsall K, Turmaine M, DiFiglia M, Aronin N, Bates GP. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? Lancet (London, England). 351: 131-3. PMID 9439509 DOI: 10.1016/S0140-6736(97)08360-8 |
0.441 |
|
| 1997 |
Pribill I, Barnes GT, Chen J, Church D, Buckler A, Baxendale S, Bates GP, Lehrach H, Gusella MJ, Duyao MP, Ambrose CM, Gusella JF, MacDonald ME. Exon trapping and sequence-based methods of gene finding in transcript mapping of human 4p16.3. Somatic Cell and Molecular Genetics. 23: 413-27. PMID 9661704 DOI: 10.1007/Bf02673751 |
0.314 |
|
| 1997 |
Bates GP, Davies SW. Transgenic mouse models of neurodegenerative disease caused by CAG/polyglutamine expansions. Molecular Medicine Today. 3: 508-15. PMID 9430787 DOI: 10.1016/S1357-4310(97)01142-8 |
0.451 |
|
| 1997 |
Sathasivam K, Baxendale S, Mangiarini L, Bertaux F, Hetherington C, Kanazawa I, Lehrach H, Bates GP. Aberrant processing of the Fugu HD (FrHD) mRNA in mouse cells and in transgenic mice. Human Molecular Genetics. 6: 2141-9. PMID 9328479 DOI: 10.1093/Hmg/6.12.2141 |
0.408 |
|
| 1997 |
DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science (New York, N.Y.). 277: 1990-3. PMID 9302293 DOI: 10.1126/Science.277.5334.1990 |
0.453 |
|
| 1997 |
Bates GP, Mangiarini L, Mahal A, Davies SW. Transgenic models of Huntington's disease. Human Molecular Genetics. 6: 1633-7. PMID 9300654 DOI: 10.1093/hmg/6.10.1633 |
0.495 |
|
| 1997 |
Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, Bates GP, Davies SW, Lehrach H, Wanker EE. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell. 90: 549-58. PMID 9267034 DOI: 10.1016/S0092-8674(00)80514-0 |
0.468 |
|
| 1997 |
Davies SW, Turmaine M, Cozens BA, DiFiglia M, Sharp AH, Ross CA, Scherzinger E, Wanker EE, Mangiarini L, Bates GP. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell. 90: 537-48. PMID 9267033 DOI: 10.1016/S0092-8674(00)80513-9 |
0.489 |
|
| 1997 |
Sathasivam K, Amaechi I, Mangiarini L, Bates G. Identification of an HD patient with a (CAG)180 repeat expansion and the propagation of highly expanded CAG repeats in lambda phage. Human Genetics. 99: 692-5. PMID 9150744 DOI: 10.1007/s004390050432 |
0.469 |
|
| 1997 |
Mangiarini L, Sathasivam K, Mahal A, Mott R, Seller M, Bates GP. Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation. Nature Genetics. 15: 197-200. PMID 9020849 DOI: 10.1038/Ng0297-197 |
0.506 |
|
| 1996 |
Hadano S, Ishida Y, Tomiyasu H, Yamamoto K, Bates GP, Ikeda JE. Transcript map of the human chromosome 4p16.3 consisting of 627 cDNA clones derived from 1 Mb of the Huntington's disease locus. Dna Research : An International Journal For Rapid Publication of Reports On Genes and Genomes. 3: 239-55. PMID 8946164 DOI: 10.1093/Dnares/3.4.239 |
0.379 |
|
| 1996 |
Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, Lawton M, Trottier Y, Lehrach H, Davies SW, Bates GP. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 87: 493-506. PMID 8898202 DOI: 10.1016/S0092-8674(00)81369-0 |
0.472 |
|
| 1996 |
Bates G. Expanded glutamines and neurodegeneration--a gain of insight. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 18: 175-8. PMID 8867730 DOI: 10.1002/BIES.950180303 |
0.438 |
|
| 1994 |
Ambrose CM, Duyao MP, Barnes G, Bates GP, Lin CS, Srinidhi J, Baxendale S, Hummerich H, Lehrach H, Altherr M. Structure and expression of the Huntington's disease gene: evidence against simple inactivation due to an expanded CAG repeat. Somatic Cell and Molecular Genetics. 20: 27-38. PMID 8197474 DOI: 10.1007/Bf02257483 |
0.49 |
|
| 1994 |
Hummerich H, Baxendale S, Mott R, Kirby SF, MacDonald ME, Gusella J, Lehrach H, Bates GP. Distribution of trinucleotide repeat sequences across a 2 Mbp region containing the Huntington's disease gene. Human Molecular Genetics. 3: 73-8. PMID 8162055 DOI: 10.1093/Hmg/3.1.73 |
0.458 |
|
| 1994 |
Bates G, Lehrach H. Trinucleotide repeat expansions and human genetic disease. Bioessays : News and Reviews in Molecular, Cellular and Developmental Biology. 16: 277-84. PMID 8031305 DOI: 10.1002/BIES.950160411 |
0.432 |
|
| 1994 |
Cross G, Pitt T, Sharif A, Bates G, Lehrach H. False-negative result for Huntington's disease mutation. Lancet (London, England). 343: 1232. PMID 7909902 DOI: 10.1016/S0140-6736(94)92447-3 |
0.362 |
|
| 1993 |
Bates G, Lehrach H. The Huntington disease gene--still a needle in a haystack? Human Molecular Genetics. 2: 343-7. PMID 8504295 DOI: 10.1093/Hmg/2.4.343 |
0.396 |
|
| 1993 |
Snell RG, Doucette-Stamm LA, Gillespie KM, Taylor SA, Riba L, Bates GP, Altherr MR, MacDonald ME, Gusella JF, Wasmuth JJ. The isolation of cDNAs within the Huntington disease region by hybridisation of yeast artificial chromosomes to a cDNA library. Human Molecular Genetics. 2: 305-9. PMID 8499921 DOI: 10.1093/Hmg/2.3.305 |
0.342 |
|
| 1993 |
MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, Barnes G, Taylor SA, James M, Groot N, MacFarlane H, Jenkins B, Anderson MA, Wexler NS, Gusella JF, ... Bates GP, et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell. 72: 971-983. PMID 8458085 DOI: 10.1016/0092-8674(93)90585-E |
0.42 |
|
| 1993 |
Tommerup N, Aagaard L, Lund CL, Boel E, Baxendale S, Bates GP, Lehrach H, Vissing H. A zinc-finger gene ZNF141 mapping at 4p16.3/D4S90 is a candidate gene for the Wolf-Hirschhorn (4p-) syndrome. Human Molecular Genetics. 2: 1571-5. PMID 8268908 DOI: 10.1093/Hmg/2.10.1571 |
0.322 |
|
| 1992 |
Taylor SA, Snell RG, Buckler A, Ambrose C, Duyao M, Church D, Lin CS, Altherr M, Bates GP, Groot N. Cloning of the alpha-adducin gene from the Huntington's disease candidate region of chromosome 4 by exon amplification. Nature Genetics. 2: 223-7. PMID 1345173 DOI: 10.1038/Ng1192-223 |
0.381 |
|
| 1992 |
Ambrose C, James M, Barnes G, Lin C, Bates G, Altherr M, Duyao M, Groot N, Church D, Wasmuth JJ, Lehrach H, Housman D, Buckler A, Gusella JF, MacDonald ME. A novel G protein-coupled receptor kinase gene cloned from 4p16.3 Human Molecular Genetics. 1: 697-703. PMID 1338872 DOI: 10.1093/Hmg/1.9.697 |
0.351 |
|
| 1992 |
Bates GP, Valdes J, Hummerich H, Baxendale S, Le Paslier DL, Monaco AP, Tagle D, MacDonald ME, Altherr M, Ross M. Characterization of a yeast artificial chromosome contig spanning the Huntington's disease gene candidate region. Nature Genetics. 1: 180-7. PMID 1303232 DOI: 10.1038/Ng0692-180 |
0.375 |
|
| 1992 |
MacDonald ME, Novelletto A, Lin C, Tagle D, Barnes G, Bates G, Taylor S, Allitto B, Altherr M, Myers R. The Huntington's disease candidate region exhibits many different haplotypes. Nature Genetics. 1: 99-103. PMID 1302016 DOI: 10.1038/Ng0592-99 |
0.42 |
|
| 1990 |
Bu?an M, Zimmer M, Whaley WL, Poustka A, Youngman S, Allitto BA, Ormondroyd E, Smith B, Pohl TM, MacDonald M, Bates GP, Richards J, Volinia S, Gilliam TC, Sedlacek Z, et al. Physical maps of 4p16.3, the area expected to contain the Huntington disease mutation Genomics. 6: 1-15. PMID 2137426 DOI: 10.1016/0888-7543(90)90442-W |
0.318 |
|
| 1990 |
Ivens A, Flavin N, Williamson R, Dixon M, Bates G, Buckingham M, Robert B. The human homeobox gene HOX7 maps to chromosome 4p16.1 and may be implicated in Wolf-Hirschhorn syndrome. Human Genetics. 84: 473-476. PMID 1969845 DOI: 10.1007/Bf00195823 |
0.307 |
|
| Show low-probability matches. |